Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Launches of Efmody in the UK as treatment of adult and adolescent patients with the rare condition congenital adrenal hyperplasia. The launch of Efmody follows its approval by the UK Medicines & Healthcare Products Regulatory Agency in Great Britain in July 2021.
Current stock price: 56.21 pence
Year-to-date change: down 0.5%
By Arvind Bhunjun; arvindbhunjun@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.